HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Quashes Claims That Ibuprofen Worsens Infection From Coronavirus

Executive Summary

Breaking News: The European Medicines Agency says there is no evidence that ibuprofen worsens Covid‑19 and that consumers can carry on using the drug as advised by patient information. 

You may also be interested in...



Tylenol Leads OTC Acetaminophen Sales Surge After Ibuprofen Scare During Pandemic – IRI

J&J leads sales growth in OTC pain relief and allergy categories in 2020 as its brands benefited from competing products’ problems and COVID-19’s impact of consumer habits. IRI reveals winning brands that kept a focus on maintaining health in 2020.

Next Generation OTC Painkillers And Cough Syrup On Cards For German Switch Committee

Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.

UK Says Still No Evidence Vitamin D Prevents Or Treats COVID-19

Yet another rapid review by the UK's NICE finds insufficient evidence to support taking vitamin D to prevent or treat COVID-19. Nevertheless, the UK government is handing out free vitamin D supplements to clinically vulnerable groups in England from Janurary. 

Related Content

Topics

UsernamePublicRestriction

Register

RS149808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel